Pharma Sector

According to Lupin's annual report for 2022, its API arm contributed approximately 6 % to the company's total revenue

LordsMed's goal of facilitating early-stage healthcare intervention and generating Rs75 crore in revenue in six months includes expanding the distribution network.

Dr Reddy’s rituximab biosimilar has already been approved for marketing in India and over 25 emerging markets.

By February 15, the company will invest upto Rs175 crore by subscribing to shares representing a 39.4% stake in the startup.

On Thursday, Ajanta Pharma's promoter entities sold 4.3 percent of their shares for Rs 637 crore.

This is the first product approval from Jarod Facility which was inspected in Dec 2022.

On consolidated basis, Ami Organics reported 9% rise in net profit to Rs 19.04 crore on 20.2% increase in revenue from operation to Rs 146.99 crore in Q2 FY23 over Q2 FY22.

The deal has been given the green channel route approval, which means that a transaction has been informed to the competition watchdog and poses no risk of having a significant negative impact on competition

The company has received all applicable approvals from key global regulators.

The demerger of the pharmaceuticals business and the streamlining of the corporate structure were agreed upon by PEL's board of directors in October 2021, converting the company from a multi-sector conglomerate to two distinct sector-focused listed corporations in financial services and medicines.